Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

SanBio Co Ltd (4592 JP): Losses Narrow; AKUUGO Upbeat on Successful Commercial Runs; FY26 Key

SanBio Co Ltd (4592 JP): Akuugo Shipments Expected To Commence In 2QFY26, New Credit Line In Place

SanBio Co Ltd (4592 JP): Akuugo Approval Awaited; Plans Negotiation for Ischemic Stroke Trials

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sanbio-co-ltd" target="_blank" data-smartkarma-citation="entities:24540:1" rel="noopener">SanBio Co Ltd (4592 JP)</a> will launch its international offering of 6M new shares at ¥2487 per share, aiming to raise up to ¥14.9B (~ US$96M).</li>
<li>Net proceeds will be allocated for Akuugo launch in Japan, Phase 3 clinical trials of SB623 traumatic brain injury program in USA and for SB623 cerebral infarction program in Japan.</li>
<li>The current stock price being ¥2628 makes the offering attractive. SanBio remains a risky bet with probability of a high return going up with every milestone being successfully cleared.</li>
</ul>



SanBio Co Ltd (4592 JP) will launch its international offering of 6M new shares at ¥2487 per share, aiming to raise up to ¥14.9B (~ US$96M).
Net proceeds will be allocated for Akuugo launch in Japan, Phase 3 clinical trials of SB623 traumatic brain injury program in USA and for SB623 cerebral infarction program in Japan.
The current stock price being ¥2628 makes the offering attractive. SanBio remains a risky bet with probability of a high return going up with every milestone being successfully cleared.


SanBio Co Ltd (4592 JP): International Offering Attractive, Akuugo Approval Is Next Big Trigger